Deucravacitinib Shows Promise in Rheumatoid Arthritis Trials

The U.S. Food and Drug Administration has approved deucravacitinib, marketed as Sotyktu®, as the first selective tyrosine kinase 2 (TYK2) inhibitor for the treatment of adults with active psoriatic arthritis (PsA). This approval, finalized on March 6, 2026, offers a new therapeutic option for individuals grappling with this chronic inflammatory condition. Clinical trials demonstrated significant improvements in symptoms for over half of patients receiving deucravacitinib, measured by established American College of Rheumatology (ACR) response criteria.

Understanding Psoriatic Arthritis and the Role of TYK2

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis, a skin condition characterized by red, itchy, scaly patches. While, PsA can occur before skin symptoms appear, or even without any visible skin involvement. It causes inflammation in the joints, leading to pain, stiffness, and swelling. The condition can affect any joint in the body, and also involves tendons and ligaments.

TYK2 is an enzyme that plays a role in the immune response. Specifically, it’s involved in signaling pathways that contribute to inflammation. By selectively inhibiting TYK2, deucravacitinib aims to modulate the immune system and reduce the inflammatory processes driving PsA. This targeted approach distinguishes it from some older treatments that broadly suppress the immune system, potentially increasing the risk of infections.

Evidence from Clinical Trials: Efficacy and Safety

The approval of deucravacitinib is based on data from the POETYK PsA-1 and POETYK PsA-2 trials. The POETYK PsA-2 trial, a phase 3, randomized, double-blind, placebo-controlled study, followed patients for up to 52 weeks. Bristol Myers Squibb, the manufacturer, presented the findings at the American College of Rheumatology (ACR) Convergence in October 2025. The trials assessed efficacy based on ACR response criteria, which measure improvements in joint pain, swelling, and function.

As reported by Medscape Medical News, more than half of the patients treated with deucravacitinib experienced at least a 20% improvement in ACR scores. While this indicates a substantial benefit for many, it’s important to note that this is a measure of *improvement* rather than complete remission. The trials also evaluated the drug’s impact on skin symptoms, as well as its safety profile. Full details of the trial methodology, including sample sizes and specific endpoints, are available through clinical trial registries like NCT04908202 (POETYK PsA-1).

What Does This Indicate for Patients?

The introduction of deucravacitinib provides a new option for individuals whose PsA hasn’t responded adequately to existing treatments, or who experience unacceptable side effects. Current treatments for PsA include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic agents. Each of these has its own benefits and risks, and the choice of treatment depends on the individual patient’s disease severity, other medical conditions, and preferences.

Deucravacitinib is administered orally, which may be more convenient for some patients compared to injectable or intravenous therapies. However, it’s crucial to understand that, like all medications, deucravacitinib carries potential side effects. Clinical trial data will continue to be analyzed to fully characterize the long-term safety profile of the drug. Patients should discuss the potential benefits and risks with their rheumatologist to determine if deucravacitinib is an appropriate treatment option.

TYK2 Inhibition: A Broader Trend in PsA Treatment

The approval of deucravacitinib highlights the growing interest in TYK2 inhibition as a therapeutic strategy for inflammatory diseases. Rheum-Live reports that alongside deucravacitinib, zasocitinib is also demonstrating promise in inhibiting TYK2 for PsA treatment. This suggests that targeting this specific enzyme may offer a more refined approach to managing inflammation compared to broader immunosuppression.

What Comes Next: Ongoing Surveillance and Research

Following the FDA approval, ongoing surveillance will be essential to monitor the real-world safety and effectiveness of deucravacitinib. The FDA typically requires manufacturers to conduct post-market studies to gather additional data on long-term outcomes and identify any rare or unexpected side effects. Further research may also explore the potential of deucravacitinib in other inflammatory conditions beyond PsA. The Prescription Drug User Fee Act (PDUFA) date of March 6, 2026, signifies the culmination of a rigorous review process, but it also marks the beginning of a new phase of data collection and analysis. Clinicians will be closely watching for emerging data to refine treatment guidelines and optimize patient care.